ProMetic Life Sciences Inc., a biopharmaceutical company, offers technologies for drug purification, drug development, proteomics, clinical diagnostics, and the elimination of pathogens. The company is also developing products to treat anemia, neutropenia, cancer, and autoimmune disease/inflammation. The company uses its proprietary Affinity Technology, which employs its Mimetic Ligand technology (chemical hooks that selectively recognize and bind to target biomolecules) to facilitate various applications where a target biomolecule requires purification or removal. Products and Services The company is a technology provider and drug developer in the fields of hematology, oncology, and nephrology. It focuses these activities in two distinct fields; therapeutics and protein technologies. It develops therapeutics to treat blood-related disorders. Its protein technologies are used to remove pathogens from blood and extract and recover valuable proteins from plasma. Protein Technologies The Protein Technologies business unit has research & development operations in Maryland, the U.S.; and Cambridge, the U.K., as well as manufacturing operations on the Isle of Man, the U.K.; and in Joliette, Canada. This business unit focuses on the development and manufacturing of plasma-derived therapeutics based on its validated technology, the Plasma Protein Purification System (PPPS); pathogen removal and diagnostics using technology; and the manufacture of specialist filtration media for use in the manufacture of biopharmaceuticals, based on its patented Mimetic Ligand technology. PPPS: The system offers an alternative to the legacy manufacturing process (the Cohn Process) and it removes therapeutic proteins from plasma with a process that improve the recovery yield. The company owns a license to use the PPPS technology, as well as a license to manufacture and sell any products derived from the PPPS technology, and the right to sublicense to third parties those same rights. Manufacturers of a range of blood-derived products, such as Kedrion, Blue Blood, and WIBP, have signed agreements incorporating the company’s technology into their manufacturing processes for the development of therapeutic products. Purification Media: The company's bioseparation products and pathogen removal technologies are managed by its United Kingdom subsidiary ProMetic BioSciences Ltd (PBL), which has R&D facilities at the Cambridge Science Park and manufacturing operations located on the Isle of Man. 12 different bioseparation materials developed and manufactured by the company have been adopted for the manufacture of licensed biopharmaceuticals or as components of licensed medical devices or medical diagnostics. Prion Reduction Technology: The company and its partners Pathogen Removal and Diagnostic Technologies, Inc. (PRDT) and MacoPharma SA have joined forces in the development of the P-Capt filter, a prion reduction device for red cell filtration. which has earned European regulatory approval (CE Mark). The prion reduction technology incorporated into the device was developed as part of a jointventure between the company and the American Red Cross under the name ‘Pathogen Removal and Diagnostic Technologies, Inc.’ (PRDT). The company's commercial application known as the BSafE technology is to use the validated PRDT technology for prion reduction in the search for a diagnostic that would certify live cattle as BSE-tested. Therapeutics The Therapeutics division is based in Laval, Canada. The company's primary therapeutic, PBI- 1402, is an orally active compound being developed to treat different types of anemia. PBI-1402 targets anemia caused by chemotherapy and renal diseases by promoting the formation of red blood cells from bone marrow. It has expanded its clinical program for PBI-1402 into the treatment of anemia in patients with myelodysplastic syndrome (MDS), a condition also referred to as ‘preleukemia’ and is intended to initiate an additional trial in patients suffering from anemia related to chronic kidney disease. The company has partnered its proprietary synthetic compound designated as PBI-1308, with Laboratorios Dermatologicos Darier for continued development in the fields of atopic dermatitis and psoriasis. It is also developing other compounds, such as PBI-1393 and PBI-1668 for applications in cancer and autoimmune diseases fields. Significant Events In February 2008, the company entered into a license agreement for the development of two hyperimmunes with the plasma fractionator, Kedrion S.p.A. (Kedrion). Kedrion has in-licensed its technologies for the manufacturing of hyperimmune products in Europe. In March 2008, the company entered into a strategic alliance and license agreement with the Wuhan Institute of Biological Products (WIBP). WIBP gained access to the company’s PPPS for the Chinese market. In September 2008, the company signed strategic agreements with Abraxis for the development and commercialization of four biopharmaceutical products targeting underserved medical conditions. On January 5, 2009, ProMetic Life Sciences Inc. announced that it has entered into a collaboration agreement with Abraxis BioScience, Inc. to develop and commercialize various applications deriving from ProMetic's prion capture technology platform. History ProMetic Life Sciences Inc. was founded in 1992.
prometic life sciences inc (PLI:Toronto)
440 Boulevard Armand-Frappier
Laval, QC H7V 4B4
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for PLI.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact PROMETIC LIFE SCIENCES INC, please visit www.prometic.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.